Pioneer factors in hormone-dependent cancers

Nature Reviews Cancer

Volumn 12, Issue 6, 2012, Pages 381-385

  Jozwik, Kamila M ^a,b   Carroll, Jason S ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PIONEER FACTOR; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP2 GAMMA; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR TLE; UNCLASSIFIED DRUG;

ANDROGEN RECEPTOR POSITIVE PROSTATE CANCER; BREAST CANCER; CANCER THERAPY; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; DNA-BINDING PROTEINS; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HORMONES; HUMANS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS;

EID: 84861526574     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3263     Document Type: Review

References (45)

1. Zaret, K. S. & Carroll, J. S. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25, 2227-2241 (2011).
2. Cirillo, L. A. & Zaret, K. S. An early developmental transcription factor complex that is more stable on nucleosome core particles than on free DNA. Mol. Cell 4, 961-969 (1999). (Pubitemid 30054902)
3. Sekiya, T. & Zaret, K. S. Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Mol. Cell 28, 291-303 (2007). (Pubitemid 47600002)
4. Cirillo, L. A. et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 9, 279-289 (2002). (Pubitemid 34195554)
5. Grossmann, M. E., Huang, H. & Tindall, D. J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst. 93, 1687-1697 (2001). (Pubitemid 33130257)
6. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev. Cancer 2, 101-112 (2002). (Pubitemid 37328797)
7. Kininis, M. et al. Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Mol. Cell Biol. 27, 5090-5104 (2007). (Pubitemid 47068284)
8. Cirillo, L. A. et al. Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J. 17, 244-254 (1998). (Pubitemid 28041065)
9. Clark, K. L., Halay, E. D., Lai, E. & Burley, S. K. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364, 412-420 (1993). (Pubitemid 23263212)
10. Hah, N. et al. A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145, 622-634 (2011).
11. Carroll, J. S. et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43 (2005). (Pubitemid 40977938)
12. Carroll, J. S. et al. Genome-wide analysis of estrogen receptor binding sites. Nature Genet. 38, 1289-1297 (2006). (Pubitemid 44646291)
13. Lin, C. Y. et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet. 3, e87 (2007).
14. Wang, Q. et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138, 245-256 (2009).
15. Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958-970 (2008). (Pubitemid 351391952)
16. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genet. 43, 27-33 (2011).
17. Laganiere, J. et al. Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl Acad. Sci. USA 102, 11651-11656 (2005). (Pubitemid 41170781)
18. Wang, Q. et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 27, 380-392 (2007). (Pubitemid 47126935)
19. Augello, M. A., Hickey, T. E. & Knudsen, K. E. FOXA1: master of steroid receptor function in cancer. EMBO J. 30, 3885-3894 (2011).
20. Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394 (2011).
21. Sahu, B. et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 30, 3962-3976 (2011).
22. Yamaguchi, N. et al. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem. Biophys. Res. Commun. 365, 711-717 (2008). (Pubitemid 350234848)
23. Zhang, C. et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 71, 6738-6748 (2011).
24. Lee, C. S., Friedman, J. R., Fulmer, J. T. & Kaestner, K. H. The initiation of liver development is dependent on Foxa transcription factors. Nature 435, 944-947 (2005). (Pubitemid 40896319)
25. Li, Z., Tuteja, G., Schug, J. & Kaestner, K. H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 148, 72-83 (2012).
26. Holmes, K. A. et al. Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc. Natl Acad. Sci. USA 109, 2748-2753 (2012).
27. Tan, S. K. et al. AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 30, 2569-2581 (2011).
28. Woodfield, G. W., Horan, A. D., Chen, Y. & Weigel, R. J. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res. 67, 8439-8443 (2007). (Pubitemid 47437415)
29. Magnani, L., Ballantyne, E. B., Zhang, X. & Lupien, M. PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet. 7, e1002368 (2011).
30. Kouros-Mehr, H. et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13, 141-152 (2008). (Pubitemid 351163164)
31. Potter, A. S., Casa, A. J. & Lee, A. V. Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J. Cell Biochem. 113, 110-121 (2012).
32. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
33. Orso, F. et al. Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region. Biochem. J. 377, 429-438 (2004). (Pubitemid 38142198)
34. Ross-Innes, C. S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).
35. Serandour, A. A. et al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 21, 555-565 (2011).
36. Badve, S. et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin. Cancer Res. 13, 4415-4421 (2007). (Pubitemid 47219708)
37. Wolf, I. et al. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int. J. Cancer 120, 1013-1022 (2007). (Pubitemid 46214300)
38. Jain, R. K., Mehta, R. J., Nakshatri, H., Idrees, M. T. & Badve, S. S. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 58, 766-772 (2011).
39. Gee, J. M. et al. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J. Pathol. 217, 32-41 (2009).
40. Harrell, J. C. et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 66, 9308-9315 (2006). (Pubitemid 44521153)
41. Hegde, N. S., Sanders, D. A., Rodriguez, R. & Balasubramanian, S. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat. Chem. 3, 829 (2011).
42. Shears, L., Plowright, L., Harrington, K., Pandha, H. S. & Morgan, R. Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J. Urol. 180, 2196-2201 (2008).
43. Morgan, R. et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 67, 5806-5813 (2007). (Pubitemid 46985014)
44. Kikugawa, T. et al. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate 66, 1092-1099 (2006). (Pubitemid 43939214)
45. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003). (Pubitemid 36842560)